NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

Seems to me that if DCVax-L does not reach the required efficacy bar for full approval for all subgroups, then it might be the unmethylated population that it gets approved for. This is 180 degrees from what I used to think.

If they can identify mesenchymal or not soon enough, then of course we all hope they can get approval for all mesenchymals, methylated or unmethylated.

Combined; All unmethylated + all mesenchymals = a large percentage of patients.

But it is still not clear whether they can identify the mesenchymals soon enough to effectively steer them to DCVax-L. LL never says that they can, while in the same discussions she says that they can identify methylation status easily.

What percentage of those classicals that respond well to TMZ are methylated? Probably all of them.

My point is that DCVax-L was probably not given a fair test regarding the mesenchymals since they all got TMZ co therapy and yet the majority probably did not benefit from it while they certainly got some degree of immunosuppression.